We respond to “promising” survival data from phase III trial of DCVax®-L - The Brain Tumour Charity

We respond to preliminary overall survival data from phase III clinical trial that suggests DCVax-L may help extend survival for patients with newly-diagnosed or recurrent glioblastomas.

Earlier this month, preliminary overall survival data from a major trial of DCVax-L in glioblastomas was presented at the New York Academy of Sciences Frontiers in Cancer Immunotherapy 2022 conferenc… [+10273 chars]

full article...